Market news
Vericel has delivered a solid 31.4% share price gain over the past year, which naturally puts a spotlight on whether that move lines up with the cash the business is expected to generate. With the stock last closing at US$39.71, the key issue for you is whether that market value can be reconciled with what its cash flows imply through a Discounted Cash Flow (DCF) lens. The 31.4% one year return has rewarded existing holders, so any fresh money coming in now needs a clear view on what the...
WSW, NY, September 22nd, 2026, FinanceWireOn September 22, MediWound disclosed that the Department of War had added to a program it has been backing since long before most investors had heard of the company. What it
Vericel stock outlook: MACI growth, expanded Burlington capacity, BARDA burn-care support, and pipeline catalysts—see why bulls call VCEL a Buy despite premium.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for International Paper Company (IP-N) from The Globe and Mail including charting and trades.
Vericel (VCEL) has an average rating of buy and mean price target of $60, according to analysts poll
Vericel (VCEL) delivered earnings and revenue surprises of +200.00% and +7.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Directors Authorizes $200 Million Share Repurchase Program Conference Call Today at 8:30am Eastern Time BURLINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today repo
Vericel (VCEL) reported Q2 net income Thursday of $0.04 per diluted share, swinging from a net loss
BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second quarter 2026 financial results on Thursday, July 30, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Ver
This is the newest page. Registered accounts read further back.